These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [A case of small cell lung cancer with renal insufficiency effectively treated with oral etoposide administration]. Akiyama Y, Kondo H, Kimura S, Fujii Y. Gan To Kagaku Ryoho; 1995 Apr; 22(5):683-6. PubMed ID: 7717722 [Abstract] [Full Text] [Related]
15. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group. Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326 [Abstract] [Full Text] [Related]
16. [Pharmacokinetic study and side effects of chronic daily administration of oral etoposide]. Taguchi O, Yamakami T, Machishi M, Gabazza EC, Ibata H, Tsutsui K, Suzuki S. Gan To Kagaku Ryoho; 1992 Oct; 19(12):2005-9. PubMed ID: 1329670 [Abstract] [Full Text] [Related]
17. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer. Kamath SS, McCarley DL, Zlotecki RA. Radiat Oncol Investig; 1998 Oct; 6(5):226-32. PubMed ID: 9822169 [Abstract] [Full Text] [Related]
18. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer. Unsal M, Erturk D. Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592 [Abstract] [Full Text] [Related]